BridgeMD
Semaglutide Treatment for Prevention of Toxicity in High-dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation
EU CTIS ID: 2022-502139-20-00
What this study is testing
To evaluate the effect of semaglutide in reducing intensity of gastrointestinal (GI) mucositis in patients undergoing high-dosage chemotherapy followed by autologous (auto) hematopoietic stem cell transplantation (HSCT).
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Referral for auto-HSCT for relapsed diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma
- Age ≥ 18 years
- BMI ≥ 18.5
- ECOG performance status ≤ 2
- Literate in Danish and/or English
You likely can't join if
- Diabetes
- Pregnant or nursing females
- Previous or current gastrointestinal malignancy
- Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Family is defined as a first degree relative
- Genetic disorders with defective tissue repair (e.g. Fanconi anaemia)
- History of pancreatitis (acute or chronic)
See the full eligibility criteria
- Referral for auto-HSCT for relapsed diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma
- Age ≥ 18 years
- BMI ≥ 18.5
- ECOG performance status ≤ 2
- Literate in Danish and/or English
- Diabetes
- Pregnant or nursing females
- Previous or current gastrointestinal malignancy
- Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Family is defined as a first degree relative
- Genetic disorders with defective tissue repair (e.g. Fanconi anaemia)
- History of pancreatitis (acute or chronic)
- Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of < 30 ml/min/1.73 m2 as defined by KDIGO 2012 classification4
- Impaired liver function, defined as ALT ≥ 2.5 times upper normal limit at screening
- Known or suspected hypersensitivity to semaglutide or other GLP-1RA
- Inflammatory bowel disease
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.